Dipòsit Digital de Documents de la UAB 35 registres trobats  1 - 10següentfinal  anar al registre: La cerca s'ha fet en 0.01 segons. 
1.
6 p, 255.0 KB Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer : Supporting personalised screening / Román, M. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Quintana Ruiz, Maria Jesús (Institut d'Investigació Biomèdica Sant Pau) ; Ferrer, J. (Parc Hospitalari Martí i Julià) ; Sala, M. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Castells, X. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Universitat Autònoma de Barcelona
Our aim was to assess the cumulative risk of false-positive screening results, screen-detected cancer, and interval breast cancer in mammography screening among women with and without a previous benign breast disease and a family history of breast cancer. [...]
2017 - 10.1038/bjc.2017.107
British Journal of Cancer, Vol. 116 Núm. 11 (23 2017) , p. 1480-1485  
2.
8 p, 509.4 KB GEIS-21 : A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS) / Mora, J. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Castañeda, A. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Perez-Jaume, S. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ; Maradiegue, E. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Valverde, C. (Hospital Universitari Vall d'Hebron) ; Martin-Broto, J. (Universidad de Sevilla) ; Garcia Del Muro, X. (Hospital Universitari de Bellvitge) ; Cruz, O. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Cruz, J. (Hospital Universitario de Canarias (La Laguna)) ; Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ; Maurel, J. (Hospital Clínic i Provincial de Barcelona) ; Vaz, M.A. (Hospital Ramón y Cajal) ; De Alava, E. (Universidad de Sevilla) ; De Torres, C. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Universitat Autònoma de Barcelona
First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. This was a prospective, multicentric, non-randomised, open study for patients 1/240 years with newly diagnosed ES. [...]
2017 - 10.1038/bjc.2017.252
British Journal of Cancer, Vol. 117 Núm. 6 (may 2017) , p. 767-774  
3.
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib / Joensuu, Heikki (Helsinki University Hospital) ; Blay, Jean-Yves (University Claude Bernard Lyon I) ; Comandone, Alessandro (Gradenigo Hospital) ; Martin-Broto, Javier (Hosp o Virgen del Rocío (Sevilla, Andalusia)) ; Fumagalli, Elena (Fondazione IRCCS Istituto Nazionale Dei Tumori) ; Grignani, Giovanni (Candiolo Cancer Institute-FPO) ; Del Muro, Xavier Garcia (Hospital Universitari de Bellvitge) ; Adenis, Antoine (Centre Oscar Lambret) ; Valverde, Claudia (Hospital Universitari Vall d'Hebron) ; López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ; Bouche, Olivier (University Hospital Robert Debre) ; Italiano, Antoine (Comprehensive Cancer Centre. 2Institut Bergonie) ; Bauer, Sebastian (University of Duisburg- Essen) ; Barone, Carlo (University Hospital A. Gemelli) ; Weiss, Claudia (Novartis Pharma GmbH) ; Crippa, Stefania (Novartis Farma) ; Camozzi, Maura (Novartis Farma) ; Castellana, Ramon (Novartis Farmaceutica SA) ; Le Cesne, Axel (Gustave Roussy) ; Universitat Autònoma de Barcelona
This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. [...]
2017 - 10.1038/bjc.2017.290
British Journal of Cancer, Vol. 117 Núm. 9 (2017) , p. 1278-1285  
4.
6 p, 291.5 KB Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer / Martín, A.J.M. (Hospital General Universitario Gregorio Marañón) ; Ortega, I. (Gendiag) ; Font, Carme (Hospital Clínic i Provincial de Barcelona) ; Pachón, V. (Hospital Universitario Ramón y Cajal (Madrid)) ; Castellón, V. (Complejo Hospitalario de Torrecárdenas) ; Martínez-Marín, V. (Hospital Universitario La Paz (Madrid)) ; Salgado, M. (Complejo Hospitalario Universitario de Ourense) ; Martínez, E. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Calzas, J. (Hospital Universitario de Fuenlabrada) ; Rupérez, A. (Hospital Universitario Fundación Jiménez Díaz) ; Souto, Juan Carlos (Institut d'Investigació Biomèdica Sant Pau) ; Martín, M. (Hospital General Universitario Gregorio Marañón) ; Salas, E. (Gendiag) ; Soria Fernández, José Manuel (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. Outpatients with cancer should be periodically assessed for VTE risk, for which the Khorana score is commonly recommended. [...]
2018 - 10.1038/s41416-018-0027-8
British Journal of Cancer, Vol. 118 Núm. 8 (january 2018) , p. 1056-1061  
5.
6 p, 380.2 KB Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer : final results of a randomised phase 2 clinical trial / Gridelli, C. (S.G. Moscati Hospital) ; Ciuleanu, Tudor Eliade (Institutui. Oncologic I. Chircuta) ; Domine, M. (Fundacion Jimenez Diaz) ; Szczesna, A. (Mazowieckie Centrum) ; Bover, I. (Son Llatzer Hospital) ; Cobo, M. (Instituto de Investigaciones Biomédicas (IBIMA)) ; Kentepozidis, N. (251 General Airforce Hospital) ; Zarogoulidis, K. (Papanikolaou General Hospital) ; Kalofonos, C. (University Hospital of Patras) ; Kazarnowisz, A. (Oddzial Onkologiiz Pododdziatem) ; Korozan, M. (Hospicjum Dutkiewicza SAC) ; de las Peñas, R (Hospital Provincial de Castellon) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Chella, A. (A.O.U. di Pisa Hospital) ; Griesinger, F. (Pius Hospital) ; Bournakis, E. (University Hospital "Aretaieion") ; Sadjadian, P. (Johannes Wesling Klinikum) ; Kotsakis, A. (University General Hospital of Larissa) ; Chinet, T. (Hopital Ambroise Paré) ; Syrigos, K.N. (General Hospital of Thoracic Diseases "Sotiria") ; Correale, P. (University Hospital of Siena) ; Gallou, C. (Vaxon-Biotech) ; Jamet, J.M. (Vaxon-Biotech) ; Vetsika, E.K. (University General Hospital of Heraklion) ; Kosmatopoulos, K. (Vaxon-Biotech) ; Georgoulias, V. (University General Hospital of Heraklion) ; Universitat Autònoma de Barcelona
The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC). [...]
2020 - 10.1038/s41416-020-0785-y
British Journal of Cancer, Vol. 122 Núm. 10 (december 2020) , p. 1461-1466  
6.
10 p, 598.8 KB Liver transplantation in metastatic colorectal cancer : are we ready for it? / Ros Montañá, Javier (Vall d'Hebron Institut d'Oncologia) ; Salva, Francesc (Vall d'Hebron Institut d'Oncologia) ; Dopazo, Cristina (Hospital Universitari Vall d'Hebron) ; López, Daniel (Vall d'Hebron Institut d'Oncologia) ; Saoudi, Nadia (Vall d'Hebron Institut d'Oncologia) ; Baraibar, Iosune (Vall d'Hebron Institut d'Oncologia) ; Charco, Ramon (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Colorectal cancer (CRC) is a prevalent disease worldwide, with more than 50% of patients developing metastases to the liver. Five-year overall survival remains modest among patients with metastatic CRC (mCRC) treated with conventional therapies however, liver transplantation in a highly selected population can improve clinical outcomes with an impressive 5-year overall survival of 83%. [...]
2023 - 10.1038/s41416-023-02213-1
British Journal of Cancer, Vol. 128 (march 2023) , p. 1797-1806  
7.
16 p, 581.3 KB Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer : a systematic review for the European Commission Initiative on Breast Cancer (ECIBC) / Canelo Aybar, Carlos Gilberto (Institut d'Investigació Biomèdica Sant Pau) ; Posso, M. (Hospital del Mar (Barcelona, Catalunya)) ; Montero, N. (Centro Cochrane Iberoamericano) ; Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ; Saz-Parkinson, Zuleika (European Commission. Joint Research Centre (JRC)) ; Duffy, Stephen W (Wolfson Institute of Preventive Medicine. Queen Mary University of London) ; Follmann, M. (German Cancer Society) ; Gräwingholt, A. (Radiologie am Theater) ; Giorgi Rossi, P. (Epidemiology Unit. Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia) ; Alonso-Coello, Pablo (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ; Universitat Autònoma de Barcelona
Background: Although mammography screening is recommended in most European countries, the balance between the benefits and harms of different screening intervals is still a matter of debate. This review informed the European Commission Initiative on Breast Cancer (BC) recommendations. [...]
2022 - 10.1038/s41416-021-01521-8
British Journal of Cancer, Vol. 126 Núm. 4 (september 2022) , p. 673-688  
8.
10 p, 647.3 KB Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative / Giorgi Rossi, Paolo (Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia (Itàlia)) ; Lebeau, Annette (University Medical Center Hamburg-Eppendorf) ; Canelo Aybar, Carlos Gilberto (Institut d'Investigació Biomèdica Sant Pau) ; Saz-Parkinson, Zuleika (Instituto de Salud Carlos III) ; Quinn, Cecily (St Vincent's Hospital (Sydney)) ; Langendam, Miranda W (Amsterdam UMC. University Medical Center) ; Mcgarrigle, Helen (Cardiff and Vale UHB - General Surgery, Cardiff, UK) ; Warman, Sue (Havyatt Lodge, Havyatt Road, Langford, North Somerset UK) ; Rigau, David (Institut d'Investigació Biomèdica Sant Pau) ; Alonso-Coello, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Broeders, Mireille (Dutch Expert Centre for Screening) ; Graewingholt, Axel (Radiologie am Theater, Paderborn, NRW Germany) ; Posso, Margarita (Institut Hospital del Mar d'Investigacions Mèdiques) ; Duffy, Stephen W (Queen Mary University of London. Centre for Cancer Prevention) ; Schünemann, Holger (McMaster University Health Sciences Centre, Hamilton. Michael G. DeGroote Cochrane Canada and McGRADE Centres; Department of Health Research Methods, Evidence and Impact) ; Universitat Autònoma de Barcelona
Predicting the risk of recurrence and response to chemotherapy in women with early breast cancer is crucial to optimise adjuvant treatment. Despite the common practice of using multigene tests to predict recurrence, existing recommendations are inconsistent. [...]
2021 - 10.1038/s41416-020-01247-z
British Journal of Cancer, Vol. 124 (february 2021) , p. 1503-1512  
9.
6 p, 754.7 KB Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial / Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France) ; André, Thierry (Oncology Multidisciplinary Research Group (GERCOR)) ; Taieb, Julien (UMR-S 1147, INSERM) ; Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy) ; Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Hickish, Tamas (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology) ; Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR)) ; Universitat Autònoma de Barcelona
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. [...]
2019 - 10.1038/s41416-019-0521-7
British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317  
10.
4 p, 972.8 KB Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma : implications for biomarker-driven clinical trials / Montal, Robert (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Andreu-Oller, Carmen (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Bassaganyas, Laia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Esteban-Fabró, Roger (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moran, S (Institut d'Investigació Biomèdica de Bellvitge) ; Montironi, Carla (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moeini, Agrin (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Pinyol, Roser (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Peix, Judit (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cabellos, Laia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Villanueva, Augusto (Icahn School of Medicine at Mount Sinai) ; Sia, Daniela (Icahn School of Medicine at Mount Sinai) ; Mazzaferro, Vincenzo (University of Milan and Gastrointestinal Surgery and Liver Transplantation Unit. Fondazione IRCCS. Istituto Nazionale dei Tumori) ; Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Llovet, Josep M. (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. [...]
2019 - 10.1038/s41416-019-0513-7
British Journal of Cancer, Vol. 121 Núm. 4 (13 2019) , p. 340-343  

Dipòsit Digital de Documents de la UAB : 35 registres trobats   1 - 10següentfinal  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.